SCHEMBL2107430

SCHEMBL2107430

Cc1ccc(S(=O)(=O)[C@H]2CN[C@H](C(=O)O)C2)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.40
GRIA2 P42262 1/20 0.40
EPHX2 P34913 6/20 0.38
ALDH1A1 P00352 3/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MEP1B Q16820 1/20 0.37
GFER P55789 2/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
ALOX12 P18054 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2106278 0.87 GRIK1 (0.39) GRIK1GRIA2GAA
SCHEMBL696268 0.79 CTSS (0.63)
Hydrochloric Acid SCHEMBL695404 0.78 CTSS (0.62)
SCHEMBL2105653 0.76 GRIK1 (0.41) GRIK1GRIA2CYP1A2CYP2D6ALOX15
SCHEMBL2106429 0.76 CTSS (0.38) GRIK1GRIA2POLBCYP1A2CYP2D6
SCHEMBL6581957 0.75 ALDH1A1 (0.43) EPHX2ALDH1A1HPGDMEP1BGFER
SCHEMBL15170415 0.74 MEN1 (0.38) GRIK1GRIA2MEN1KMT2ACYP1A2
SCHEMBL696063 0.74 AKR1B1 (0.40) GRIK1GRIA2EPHX2HPGD
SCHEMBL15173261 0.74 GRIK1 (0.42) GRIK1GRIA2ALDH1A1HPGDHSD17B10
SCHEMBL2105321 0.73 CTSB (0.48) GRIK1GRIA2KMT2ACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 GRIK1 3044/4885GRIA2 2010/4885EPHX2 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.